-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Upgrades Bristol-Myers Squibb to Buy, Raises Price Target to $65

Benzinga·01/07/2026 15:22:24
语音播报
UBS analyst Michael Yee upgrades Bristol-Myers Squibb (NYSE:BMY) from Neutral to Buy and raises the price target from $46 to $65.